{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:37:09Z","timestamp":1787031429722,"version":"build-2736575974"},"reference-count":21,"publisher":"SAABRON PRESS","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma which may predispose individuals to development of secondary malignancies (SMs). The Surveillance, Epidemiology, and End Results (SEER) database is a comprehensive registry of cancer patients in the United States reporting on a wide set of demographic variables. Using the SEER-18 dataset, analyzing patients from 2000 to 2018, we aimed to assess the incidence of SMs in WM patients. Patient characteristics such as gender, age, race, and latency were identified, and respective standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated to compare to the general population. Of the 4,112 eligible WM patients identified, SMs were reported in 699 (17%) patients. The overall risk of developing SM, second primary malignancy, and secondary hematological malignancy was significantly higher in WM patients compared to the general population. Our findings show that WM patients had a 53% higher risk of SMs relative to the general population, and an AER of 102.69 per 10,000. Although the exact mechanism is unclear, the risk of SM development may be due to genetic predisposition, immune dysregulation, or treatment-induced immune suppression.<\/jats:p>","DOI":"10.46989\/001c.90436","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T10:07:53Z","timestamp":1704449273000},"source":"Crossref","is-referenced-by-count":3,"title":["Incidence and Risk of Secondary Malignancy in Patients with Waldenstr\u00f6m Macroglobulinemia: A Population-Based Analysis"],"prefix":"10.46989","volume":"6","author":[{"given":"Mohammad Ebad Ur","family":"Rehman","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02maedm12","id-type":"ROR","asserted-by":"publisher"}],"name":"Rawalpindi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Hameed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02atdvd89","id-type":"ROR","asserted-by":"publisher"}],"name":"Sarasota Memorial Hospital","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zunairah","family":"Shah","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0530erx71","id-type":"ROR","asserted-by":"publisher"}],"name":"Weiss Memorial Hospital","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1385-0090","authenticated-orcid":false,"given":"Omer S","family":"Ashruf","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04q9qf557","id-type":"ROR","asserted-by":"publisher"}],"name":"Northeast Ohio Medical University","department":["College of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Ali","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00xcryt71","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Arkansas for Medical Sciences","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Faraz","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02maedm12","id-type":"ROR","asserted-by":"publisher"}],"name":"Rawalpindi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Basit","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02maedm12","id-type":"ROR","asserted-by":"publisher"}],"name":"Rawalpindi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israr","family":"Khan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04p5zd128","id-type":"ROR","asserted-by":"publisher"}],"name":"Hackensack Meridian Health","department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Fazal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02maedm12","id-type":"ROR","asserted-by":"publisher"}],"name":"Rawalpindi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Iftikhar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03m2x1q45","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Arizona","department":["Department of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulqadir J","family":"Nashwan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02zwb6n98","id-type":"ROR","asserted-by":"publisher"}],"name":"Hamad Medical Corporation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0499dwk57","id-type":"ROR","asserted-by":"publisher"}],"name":"Roswell Park Cancer Institute","department":["Division of Hematology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03xjacd83","id-type":"ROR","asserted-by":"publisher"}],"name":"Cleveland Clinic","department":["Department of Hematology and Medical Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/annonc\/mdj111","article-title":"Characterization of familial Waldenstr\u00f6m's macroglobulinemia","volume":"17","author":"S.P. Treon","year":"2006","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3816\/clml.2011.n.042","article-title":"Heterogeneity of histological transformation events in Waldenstr\u00f6m's macroglobulinemia (WM) and related disorders","volume":"11","author":"R G Owen","year":"2011","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"e2018004","DOI":"10.4084\/mjhid.2018.004","article-title":"Waldenstrom\u2019s macroglobulinemia: an update","volume":"10","author":"Maddalena Mazzucchelli","year":"2018","journal-title":"Mediterranean journal of hematology and infectious diseases","ISSN":"https:\/\/id.crossref.org\/issn\/2035-3006","issn-type":"print"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-3-319-13150-4_7","article-title":"Biology, Prognosis, and Therapy of Waldenstr\u00f6m Macroglobulinemia","author":"Jorge J. Castillo","year":"2015","journal-title":"Non-Hodgkin Lymphoma: Pathology, Imaging, and Current Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/0927-3042","issn-type":"print"},{"issue":"30","key":"ref5","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1200\/jco.2012.41.8681","article-title":"Second malignant neoplasms: assessment and strategies for risk reduction","volume":"30","author":"Marie E. Wood","year":"2012","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"15_suppl","key":"ref6","doi-asserted-by":"crossref","first-page":"e18566","DOI":"10.1200\/jco.2011.29.15_suppl.e18566","article-title":"Site-specific relative risks of second primary malignancies among patients with Waldenstrom macroglobulinemia","volume":"29","author":"L.M. Brown Philpot","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"ref7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"M. Varettoni","year":"2012","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"4","key":"ref8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10552-015-0545-0","article-title":"Second primary malignancies in Waldenstrom\u2019s macroglobulinemia: a US population-based study","volume":"26","author":"Smith Giri","year":"2015","journal-title":"Cancer Causes & Control","ISSN":"https:\/\/id.crossref.org\/issn\/0957-5243","issn-type":"print"},{"issue":"15_Supplement","key":"ref9","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1158\/1538-7445.am2015-3709","article-title":"Second cancers following Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma in the United States: analysis of Surveillance, Epidemiology and End Results (SEER) registry data, 1992 - 2011","volume":"75","author":"Mary L. McMaster","year":"2015","journal-title":"Cancer Research","ISSN":"https:\/\/id.crossref.org\/issn\/0008-5472","issn-type":"print"},{"issue":"13","key":"ref10","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with W aldenstr\u00f6m macroglobulinemia: An analysis of the SEER database","volume":"121","author":"Jorge J. Castillo","year":"2015","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"ref11","article-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"S.H. Swerdlow","year":"2008"},{"issue":"Supplement 1","key":"ref12","doi-asserted-by":"publisher","first-page":"10963","DOI":"10.1182\/blood-2022-165191","article-title":"Second Primary Malignancy in Waldenstr\u00f6m Macroglobulinemia: Insights from a Population-Based Analysis","volume":"140","author":"Mohammad Ebad Ur Rehman","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"Supplement 1","key":"ref13","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1182\/blood-2018-99-115725","article-title":"Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group","volume":"132","author":"Maria Gavriatopoulou","year":"2018","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"25","key":"ref14","doi-asserted-by":"publisher","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstr\u00f6m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Jorge J. Castillo","year":"2014","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3816\/clml.2011.n.016","article-title":"Associated malignancies in patients with Waldenstr\u00f6m's macroglobulinemia and their kin","volume":"11","author":"Christina Hanzis","year":"2011","journal-title":"Clinical Lymphoma Myeloma and Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/2152-2650","issn-type":"print"},{"issue":"2","key":"ref16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/annonc\/mdr537","article-title":"Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data","volume":"23","author":"R.P. Ojha","year":"2012","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/annonc\/mdr119","article-title":"Risk of second cancers in Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"M. Varettoni","year":"2012","journal-title":"Annals of Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0923-7534","issn-type":"print"},{"issue":"13","key":"ref18","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.29334","article-title":"Incidence of secondary malignancies among patients with Waldenstr\u00f6m macroglobulinemia: an analysis of the SEER database","volume":"121","author":"Jorge J. Castillo","year":"2015","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"2","key":"ref19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1309\/r01vxg46mfcdvnhl","article-title":"Diffuse large B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma\/Waldenstr\u00f6m macroglobulinemia: clinicopathologic features of 12 cases","volume":"120","author":"Pei Lin","year":"2003","journal-title":"American journal of clinical pathology","ISSN":"https:\/\/id.crossref.org\/issn\/0002-9173","issn-type":"print"},{"issue":"1","key":"ref20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5858\/arpa.2011-0429-cr","article-title":"Burkitt lymphoma arising from lymphoplasmacytic lymphoma following acquisition of MYC translocation and loss of the ETV6 tumor suppressor gene","volume":"137","author":"Deniz Peker","year":"2013","journal-title":"Archives of Pathology & Laboratory Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1543-2165","issn-type":"print"},{"issue":"2","key":"ref21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1200\/jco.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasia\/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs","volume":"27","author":"Xavier Leleu","year":"2009","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/90436-incidence-and-risk-of-secondary-malignancy-in-patients-with-waldenstrom-macroglobulinemia-a-population-based-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:47:55Z","timestamp":1750078075000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/90436-incidence-and-risk-of-secondary-malignancy-in-patients-with-waldenstrom-macroglobulinemia-a-population-based-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.90436","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}